Nomogram predicting the prognosis of primary liver cancer after radiofrequency ablation combined with transcatheter arterial chemoembolization

Table 1 Comparison of clinical data between the recurrence and metastasis group and the non-recurrence and metastasis group, n (%)

Index	Recurrence and metastasis group (n = 92)	Non-recurrence and metastasis group (n = 58)	t/χ2/Z	P value
Gender			1.039	0.308
Male	63 (68.48)	35 (60.34)
Female	29 (31.52)	23 (39.66)
TNM stage			-0.051	0.960
T2	24 (26.09)	10 (17.24)
T3	19 (20.65)	20 (34.48)
T4	49 (53.26)	28 (48.28)
Degree of tumor differentiation			2.592	0.107
I/II	60 (65.22)	45 (77.59)
III/IV	32 (34.78)	13 (22.41)
Coated complete			1.039	0.308
Yes	63 (68.48)	35 (60.34)
No	29 (31.52)	23 (39.66)
The tumor is adjacent to large blood vessels			0.575	0.448
Yes	16 (17.39)	13 (22.41)
No	76 (82.61)	45 (77.59)
Number of lesions			1.529	0.216
≤ 3	70 (76.09)	49 (84.48)
> 3	22 (23.91)	9 (15.52)
Child-Pugh			1.558	0.212
Grade A	54 (58.70)	28 (48.28)
Grade B	38 (41.30)	30 (51.72)
HBsAg			0.214	0.643
Positive	65 (70.65)	43 (74.14)
Negative	27 (29.35)	15 (25.86)
Combined portal collateral circulation			8.272	0.004
Yes	42 (45.65)	13 (22.41)
No	50 (54.35)	45 (77.59)
Portal vein tumor thrombosis			19.244	< 0.001
Yes	72 (78.26)	25 (43.10)
No	20 (21.74)	33 (56.90)
Vascular invasion			8.191	0.004
Yes	28 (30.43)	6 (10.34)
No	64 (69.57)	52 (89.66)
Combined liver cirrhosis			24.017	< 0.001
Yes	60 (65.22)	14 (24.14)
No	32 (34.78)	44 (75.86)
Antiviral therapy			1.468	0.226
Yes	43 (46.74)	33 (56.90)
No	49 (53.26)	25 (43.10)
Smoking			0.702	0.402
Yes	54 (58.70)	30 (51.72)
No	38 (41.30)	28 (48.28)
Alcohol drinking			0.865	0.352
Yes	50 (54.35)	27 (46.55)
No	42 (45.65)	31 (53.45)
Age (year)	58.26 ± 12.95	60.11 ± 9.24	0.946	0.346
Greatest tumor diameter (cm)	3.87 ± 0.92	4.02 ± 0.58	1.110	0.269
AFP (μg/L)	457.26 ± 70.47	419.28 ± 67.73	3.263	0.001
Blood platelet (× 109/L)	102.45 ± 30.52	99.57 ± 30.26	0.565	0.573
Prothrombin time (seconds)	14.77 ± 2.21	14.81 ± 2.55	0.102	0.919
Total bilirubin (μmol/L)	19.66 ± 5.72	20.08 ± 4.39	0.477	0.634
Cartesian score (U/L) score	83.47 ± 20.22	79.87 ± 20.15	1.063	0.289
Albumin (g/L)	31.04 ± 3.22	30.89 ± 3.35	0.274	0.785
AFU (U/L)	42.36 ± 6.70	38.22 ± 5.53	3.935	< 0.001
GGT (U/L)	45.37 ± 7.74	48.25 ± 8.45	2.142	0.034
PNI	42.39 ± 9.79	48.36 ± 8.23	3.862	< 0.001
NLR	2.46 ± 0.72	2.57 ± 0.82	0.863	0.389
CRP (mg/L)	2.83 ± 0.82	2.91 ± 0.93	0.552	0.582
AST (U/L)	145.26 ± 38.57	150.11 ± 30.15	0.813	0.417
ALT (U/L)	85.39 ± 20.58	80.22 ± 25.21	1.372	0.172

AFP: Alpha-fetoprotein; AFU: α-L-fucosidase; GGT: γ-glutamyl transpeptidase; PNI: Prognostic nutritional index; NLR: Lymphocyte ratio; CRP: C-reactive protein; AST: Aspartate aminotransferase: ALT: Alanine aminotransferase.

Table 2 Multivariate logistic regression analysis of the prognosis of hepatocellular carcinoma patients treated with radiofrequency ablation combined with transcatheter arterial chemoembolization

Variable	Assignment	β	SE	Wald	P value	OR	95%CI
							Lower limit	Upper limit
Combined portal collateral circulation	0 = No, 1 = Yes	0.652	0.489	1.776	0.183	1.919	0.736	5.002
Portal vein tumor thrombosis	0 = No, 1 = Yes	1.570	0.491	10.212	0.001	4.806	1.835	12.589
Vascular invasion	0 = No, 1 = Yes	1.229	0.606	4.107	0.043	3.418	1.041	11.218
Cirrhosis	0 = No, 1 = Yes	1.330	0.474	7.874	0.005	3.783	1.494	9.580
AFP		0.010	0.003	8.196	0.004	1.010	1.003	1.016
AFU		0.127	0.041	9.385	0.002	1.135	1.047	1.231
GGT		-0.046	0.030	2.385	0.123	0.955	0.900	1.013
PNI		-0.083	0.028	9.174	0.002	0.920	0.872	0.971

AFP: Alpha-fetoprotein; AFU: α-L-fucosidase; GGT: γ-glutamyl transpeptidase; PNI: Prognostic nutritional index; B and β: Regression coefficient; SE: Standard error; OR: Odds ratio; CI: Confidence interval.